ArticleAmerican journal of cancer research2025
A predictive model based on BRCA1/2, POLE, TP53, and MSH6 mutations for immunotherapy response in advanced endometrial cancer.
Yancai Jia et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.